Neurocrine Biosciences Inc. (NBIX) exhibits 96.0% gross margins and 15.7% return on invested capital within Health Care (Biotechnology: Biological Products (No Diagnostic Substances)), balanced against a 22.8x enterprise multiple and 4.8% implied options volatility.
Sustained 96.0% gross profitability converts into 21.6% operating margin and 15.7% ROIC, outpacing sector cost of capital.
ROIC: 15.7% // GM: 96.0%YoY revenue trajectory of +21.4% paired with 5.03% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +21.4% // FCF YLD: 5.03%Altman Z-Score of 8.13 and Piotroski F-Score of 9/9 indicate low near-term refinancing stress.
ALTMAN Z: 8.13 // F-SCORE: 9/9Trading at 31.1x trailing P/E (26.1x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 31.1x // EV/EBITDA: 22.8xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $146.10 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Biological Products (No Diagnostic Substances) require continuous execution to defend 16.7% net margins.
NET MARGIN: 16.7% // D/E: 0.18x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for NBIX & activate live FRED threshold breach alerts.